نمایش مختصر رکورد

dc.contributor.authorIzadi, Sadeghen_US
dc.contributor.authorBorhani-Haghighi, Afshinen_US
dc.contributor.authorBastani, Kamalen_US
dc.contributor.authorKardeh, Baharehen_US
dc.contributor.authorYadollahi-Khales, Golnazen_US
dc.contributor.authorNeydavoodi, Mojtabaen_US
dc.date.accessioned1399-07-09T07:49:10Zfa_IR
dc.date.accessioned2020-09-30T07:49:10Z
dc.date.available1399-07-09T07:49:10Zfa_IR
dc.date.available2020-09-30T07:49:10Z
dc.date.issued2018-09-01en_US
dc.date.issued1397-06-10fa_IR
dc.date.submitted2018-09-24en_US
dc.date.submitted1397-07-02fa_IR
dc.identifier.citationIzadi, Sadegh, Borhani-Haghighi, Afshin, Bastani, Kamal, Kardeh, Bahareh, Yadollahi-Khales, Golnaz, Neydavoodi, Mojtaba. (2018). Circulating Levels of Interleukin-10 and -17 in Patients with Cerebral Sinovenous Thrombosis (CSVT) in Acute and Subacute Stages: A Prospective Case-Control Study. Iranian Journal of Immunology, 15(3), 221-227. doi: 10.22034/iji.2018.39391en_US
dc.identifier.issn1735-1383
dc.identifier.issn1735-367X
dc.identifier.urihttps://dx.doi.org/10.22034/iji.2018.39391
dc.identifier.urihttps://iji.sums.ac.ir/article_39391.html
dc.identifier.urihttps://iranjournals.nlai.ir/handle/123456789/329504
dc.description.abstractBackground: Cerebral sinovenous thrombosis (CSVT) is a neurovascular disorder that occurs when a blood clot develops in a vein near the brain. Evaluating the subsequent changes in inflammatory cytokines can better reveal the underlying pathogeneses. Objective: To assess the serum levels of interleukin-10 (an anti-inflammatory cytokine) and IL-17 (a pro-inflammatory cytokine) in patients with aseptic non-vasculitic CSVT. Methods: In this prospective case-control study, 31 patients with aseptic non-vasculitic CSVT (admitted in Namazi Hospital, Shiraz University of Medical Sciences, Shiraz, Iran) were enrolled. IL-10 and IL-17 serum levels were measured at diagnosis, before initiation of treatment (acute stage), 3 months later (subacute stage). These cytokines were also measured in samples obtained from 30 gender- and age-matched healthy subjects, which were considered as control values. Results: Patients' IL-10 and IL-17 levels were higher in both acute and subacute stages as compared to controls. However, no significant differences existed between the acute stage and control groups for both cytokines. Moreover, subacute levels were significantly higher than their acute and control levels. Conclusion: This study demonstrated the alteration of IL-10 and IL-17 levels in aseptic non-vasculitic CSVT. The rise in subacute IL-10 can be explained by the assumption that IL-10 is released as an anti-inflammatory response to subside the effects of IL-17 mediated reactions. More importantly, the immediate sampling in the acute stage did not allow enough time for triggering the immune system to produce such mediators. However, a balance was established between IL-10 and IL-17 in the subacute stage to prevent further tissue damage.en_US
dc.languageEnglish
dc.language.isoen_US
dc.publisherShiraz Institute for Cancer Researchen_US
dc.relation.ispartofIranian Journal of Immunologyen_US
dc.relation.isversionofhttps://dx.doi.org/10.22034/iji.2018.39391
dc.titleCirculating Levels of Interleukin-10 and -17 in Patients with Cerebral Sinovenous Thrombosis (CSVT) in Acute and Subacute Stages: A Prospective Case-Control Studyen_US
dc.typeTexten_US
dc.typeOriginal Articleen_US
dc.contributor.departmentClinical Neurology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran,en_US
dc.contributor.departmentClinical Neurology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran,en_US
dc.contributor.departmentClinical Neurology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran,en_US
dc.contributor.departmentClinical Neurology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran,en_US
dc.contributor.departmentUniversity of Illinois hospital, neurology department, Chicago, Illinoisen_US
dc.contributor.departmentClinical Neurology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran,en_US
dc.citation.volume15
dc.citation.issue3
dc.citation.spage221
dc.citation.epage227
nlai.contributor.orcid0000-0002-4131-7990


فایل‌های این مورد

فایل‌هااندازهقالبمشاهده

فایلی با این مورد مرتبط نشده است.

این مورد در مجموعه‌های زیر وجود دارد:

نمایش مختصر رکورد